Skip to Content

Bayer AG ADR

BAYRY: PINX (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$74.20RcyynrzZwqr

Bayer Earnings: Solid Results Aided by Litigation Win, Cost-Cutting, and Innovation Advancements

Bayer reported first-quarter results slightly above our expectations, but we are not making any changes to the firm’s fair value estimate. We continue to view Bayer as undervalued with the market overly concerned about litigation pressures and underappreciating the firm’s cost-cutting plan and growth potential from innovative products.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of BAYRY so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center